Clinical trials Below are current clinical trials.10 studies in CAR-T Cell Therapy Program (open studies only). Filter this list of studies by location, status and more. A Study to Evaluate the Safety and Effectiveness of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this single-dose escalation study is to evaluate the safety and effectiveness of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma. Axicabtagene Ciloleucel Expanded Access Study Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma. A Study Evaluating the Safety and Effectiveness of JCAR017 in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to determine the effectiveness and safety of JCAR017 in adult subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the effectiveness and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated. A Multi-Center Study Evaluating KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia Rochester, Minn. This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) in pediatric or adolescent subjects. Open-label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T-cells (CT053) in Patients Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla. The purpose of this study is to evaluate Chimeric Antigen Receptor T Cells targeting BCMA in patients with myeloma. A Study to Compare the Effectiveness and Safety of bb2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to compare the effectiveness and safety of bb2121 versus standard triplet regimens in subjects with relapsed and refractory multiple myeloma (RRMM). A Safety and Effectiveness Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the safety and effectiveness of defibrotide for the prevention of CAR-T-associated neurotoxicity in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) receiving Yescarta®. Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Subjects who received at least one GM T cell infusion, will be asked to roll-over to this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol. A Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination eith Either Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14) Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn. The primary objective of this study is to estimate the safety and effectiveness of axicabtagene ciloleucel in combination with either rituximab or lenalidomide, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell lymphoma. Study of bb2121 in Multiple Myeloma Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM). Request an Appointment at Mayo Clinic Frequently asked questionsResources for medical professionals Oct. 15, 2019 Share on: FacebookTwitter Show references Locke FL, et al. Clinical and biologic covariates of outcomes in zuma-1: A pivotal trial of axicabtagene ciloleucel (AXI-CEL; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Presentation. 2017 annual meeting of European Hematology Association, June 24, 2017, Madrid, Spain. https://learningcenter.ehaweb.org/eha/2017/22nd/181753/yi.lin.clinical.and.biologic.covariates.of.outcomes.in.zuma-1.a.pivotal.trial.html?f=m3. Accessed Oct. 27, 2017. Neelapu SS, et al. Chimeric antigen receptor T-cell therapy: Assessment and management of toxicities. Nature Reviews Clinical Oncology. 2018;15:47. CAR-T Cell Therapy ProgramDepartment homeSectionsOverviewAbout CAR-T cell therapyOur programDoctorsFrequently asked questionsClinical trialsResources for medical professionals Research: It's All About Patients SectionsRequest an AppointmentOverviewAbout CAR-T cell therapyOur programDoctorsFrequently asked questionsClinical trialsResources for medical professionals ORG-20404311 Departments & Centers Medical Departments & Centers CAR-T Cell Therapy Program